The Lancet
The Lancet is Britain's leading general medical journal and the other main home of practice-changing cancer trials, with a stronger global-health and policy voice than NEJM.
Overview
The Lancet appears weekly and publishes practice-changing oncology phase 3 trials (CheckMate 649, KEYNOTE-048, CARTITUDE-1, TRANSFORM), the Global Burden of Disease series, and Lancet Commissions that shape cancer policy. Elsevier hybrid model: subscription with an open-access option; abstracts free. Known for editorial campaigning on health inequality and for the HPV-vaccination and cancer-survival population studies that appear in this corpus.
Patients newly diagnosed with an advanced grade 2 or 3 neuroendocrine tumour of the gut or pancreas that shows somatostatin receptors on imaging can now receive lutetium dotatate as their first treatment, gaining more than a year of additional disease control and a much higher chance of tumour shrinkage. It does not settle whether radioligand therapy is better than other first-line options such as capecitabine-temozolomide or everolimus, and long-term marrow safety with earlier use needs surveillance.
For men who still have a working hormone treatment option but whose cancer is progressing, offering the PSMA radioligand therapy sooner - before chemotherapy - delayed disease progression, though it did not clearly extend how long men lived once the very high rate of patients switching over is accounted for.
For men whose prostate cancer has grown after chemotherapy, a PSMA-targeted radioactive treatment worked at least as well as, and was gentler than, the chemotherapy drug it replaced - provided a PET scan first confirms the cancer takes up the PSMA tracer.
PSMA PET-CT is the preferred staging investigation for high-risk prostate cancer and for biochemical recurrence, though most treatment trials were designed with conventional imaging.
A nuclear medicine physician-scientist who worked on the practice-changing TheraP and LuPSMA trials in Australia and has moved through Fred Hutchinson to UCLA in 2026 to build a new hospital theranostics programme.
London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises.
Urologist who co-led proPSMA, the trial that showed PSMA PET should replace CT and bone scan for staging prostate cancer.
Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours.
Led LATITUDE and PEACE-1, which put abiraterone into first-line metastatic prostate cancer.
A German nuclear medicine physician whose 2015 study of gallium-68 PSMA PET scanning for prostate cancer became one of the most-cited papers in the field, and who now leads theranostics research in Munich.
Led proPSMA and TheraP, the trials that proved PSMA PET beats conventional imaging and that lutetium-PSMA beats chemotherapy.
Principal investigator of the VISION trial that made lutetium-PSMA a standard prostate cancer treatment.
An Australian nuclear medicine pioneer who built Peter MacCallum Cancer Centre's molecular imaging and therapy service into a world-renowned unit over three decades, and now runs an independent theranostics centre in Melbourne.
Led NETTER-2, which moved lutetium dotatate into first-line treatment of higher-grade neuroendocrine tumours.
Patients newly diagnosed with an advanced grade 2 or 3 neuroendocrine tumour of the gut or pancreas that shows somatostatin receptors on imaging can now receive lutetium dotatate as their first treatment, gaining more than a year of additional disease control and a much higher chance of tumour shrinkage. It does not settle whether radioligand therapy is better than other first-line options such as capecitabine-temozolomide or everolimus, and long-term marrow safety with earlier use needs surveillance.
PSMA PET-CT is the preferred staging investigation for high-risk prostate cancer and for biochemical recurrence, though most treatment trials were designed with conventional imaging.